Abstract
We determined the proliferation rate and apoptotic activity of glycogen‐rich carcinomas of the breast as opposed to non‐clear cell tumors by means of MIB‐1 immunohistochemistry and in situ detection of oligonucleosomal fragments (TUNEL reaction). The retrospective biopsy series included six invasive clear cell carcinomas of the glycogen‐rich type as well as 15 randomly selected cases of invasive ductal carcinoma without evidence of glycogen storage. Three patients in the clear cell group and seven patients in the control cohort developed lymph‐node metastasis. The MIB‐1 labeling index of glycogen‐rich carcinomas averaged 9.05%, while that of the controls was 30.03%. Apoptotic nuclei were present in a mean of 1.26% of glycogen‐rich carcinoma cells. The control tumors exhibited an average apoptotic frequency of 5.85%. Tumor size, hormone receptor status, and presence or absence of lymph node involvement were found not to correlate with either proliferation or apoptosis. We conclude that glycogen‐rich breast carcinomas are characterized by a peculiar ‘low proliferation‐low apoptosis’ cell kinetic profile. The aggressive clinical behavior of these neoplasms may possibly be accounted for by an ineffective apoptotic elimination of otherwise slowly proliferating tumor cells.
Similar content being viewed by others
References
Dina R, Eusebi V: Clear cell tumors of the breast. Sem Diagn Pathol 14: 175–182, 1997
Rosen PP: Glycogen-rich carcinoma. In: Rosen's Breast Pathology. Lippincott-Raven 1997, pp 485–487
Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC: Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 82: 1296–1302, 1998
Shen KL, Ham HJ, Ho LI, Yu CH, Chiu SC, Lee WH: The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin 11-dUTP nick end labeling. Cancer 82: 2373–2381, 1998
Toikkanen S, Joensuu H: Glycogen-rich clear cell carcinoma of the breast. Hum Pathol 22: 81–83, 1991
Hayes MMM, Seidman JD, Ashton MA: Glycogen-rich clear cell carcinoma of the breast. A clinicopathologic study of 21 cases. Am J Surg Pathol 19: 904–911, 1995
Fisher ER, Tavares J, Bulatao IS, Sass R, Fischer B and collaborating NSABP investigators: Glycogen-rich, clear cell breast cancer. Hum Pathol 16: 1085–1090, 1985
Satoh F, Umemura S, Itoh H, Miyajima Y, Tokuda Y, Tajima T, Osamura RY: Fine needle aspiration cytology of glycogen-rich clear cell carcinoma of the breast. Acta Cytol 42: 413–418, 1998
Bevilacqua P, Verderio P, Barbareschi M, Bonoldi E, Boracchi P, Palma PD, Gasparini G: Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Breast Cancer Res Treat 37: 123–133, 1996
MacGrogan G, Jollet I, Huet S, Sierankowski G, Picot V, Bonichon F, Coindre JM: Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol 10: 769–776, 1997
Veronese SM, Maisano C, Scibilia J: Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res 16:2717-2722, 1996
Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155–168, 1998
Harn HJ, Shen KL, Yueh KC, Ho LI, Yu JC, Chiu SC, Lee WH: Apoptosis occurs more frequently in intraductal carcinoma than in infiltrating duct carcinoma of human breast cancer and correlates with altered p53 expression: detected by terminal-deoxynucleotidyl-transferase-mediated dUTP-FITC nick end labelling (TUNEL). Histopathology 31: 534–539, 1997
Sierra A, Lloveras B, Castellsaugé X, Moreno L, Garcia-Ramirez M, Fabra A: Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 60: 54–60, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Varga, Z., Caduff, R. Glycogen‐rich carcinomas of the breast display unique characteristics with respect to proliferation and the frequency of oligonucleosomal fragments. Breast Cancer Res Treat 57, 215–219 (1999). https://doi.org/10.1023/A:1006285819701
Issue Date:
DOI: https://doi.org/10.1023/A:1006285819701